Clinical Trials Browser

Phase 2 × Chromosome 17 deletion × Alemtuzumab × Clear all

NCT01392079 2019-10-24

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

Phase 2 Completed

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell